SCO-094 is a dual agonist of GLP-1R and GIPR, and an injection that acts on the receptors for GLP-1 and GIP. The effects of GLP-1 and GIP are expected to be beneficial in patients with diabetes and obesity, and a Phase 1 clinical study is being prepared.

Indication

  • Obesity
  • Diabetes
  • Activation
  • Benefits
SCO-094
GLP-1R
GIPR

Pancreas

Pancreas

Insulin secretion
Glucagon secretion

Brain

Brain

Food
intake

Stomach

Stomach

Gastric
emptying

Skeletal muscle

Skeletal muscle

Glucose
consumption

Liver

Liver

Glucose
production

GIPR

Pancreas

Pancreas

Insulin
secretion

Fat

Fat

Glucose
consumption

Blood glucose level

Body weight

GLP-1R : Glucagon-like peptide 1 receptor

GIPR : Glucose-dependent insulinotropic peptide receptor

SCO-094 acts on two types of receptors, GLP-1R and GIPR. GLP-1 is known to delay gastric emptying, suppress food intake, promote insulin secretion, suppress glucagon secretion, increase glucose utilization, and inhibit hepatic glucose production. GIP is believed to stimulate insulin secretion and glucose utilization. By combining these actions, SCO-094 is expected to show strong antidiabetic and anti-obesity effects in humans.